Publication:
Clinical and Urodynamic Results of Repeated Intradetrusor Onabotulinum Toxin A Injections in Refractory Neurogenic Detrusor Overactivity: Up to 5 Injections in a Cohort of Children With Myelodysplasia

Simple item page
dc.contributor.authorŞEKERCİ, ÇAĞRI AKIN
dc.contributor.authorsSekerci, Cagri Akin; Tanidir, Yiloren; Garayev, Asgar; Akbal, Cem; Tarcan, Tufan; Simsek, Ferruh
dc.date.accessioned2022-03-12T22:24:50Z
dc.date.available2022-03-12T22:24:50Z
dc.date.issued2018
dc.description.abstractOBJECTIVE To determine the efficacy and safety of repeated intradetrusor onabotulinum toxin A (onaBoNT-A) injections in children with neurogenic detrusor overactivity due to myelodysplasia. MATERIALS AND METHODS The study group consisted of 19 children (4 boys and 15 girls) with a mean age of 10.3 +/- 3.1 years old, who had received at least 2 injections of 10 U/kg onaBoNT-A for the treatment of urinary incontinence resistant to anticholinergic treatment and clean intermittent catheterization in our clinic, between 2010 and 2015. Controlled urodynamic studies were performed at the baseline and 3 months after each injection. RESULTS Eight of the children received 3 injections, 5 children had 4 injections, and 2 children had 5 injections. From the baseline to the fifth injection, the detrusor compliance (1.3, 4.5, 10, 20.7, 18.8, and 16.6 mL/cm H2O), the maximum bladder capacity (82.0, 157.0, 191.0, 272.0, 299.0, and 210.5 mL), and the maximum detrusor pressure (55.0, 33.0, 22.0, 12.5, 16.0, and 12.5 cm H2O) were assessed. The findings significantly improved following the first, second, and third injections, when compared with the previous bladder dynamics (P <. 05), but the differences with the fourth were not statistically significant (P >. 05). The continence periods were similar under clean intermittent catheterization after all of the injections (P <. 05), and no severe side effects were observed. CONCLUSION Repeated onaBoNT-A injections are a safe treatment modality and can be offered as an effective alternative choice, instead of more invasive surgery, in children with neurogenic detrusor overactivity due to myelodysplasia. (C) 2017 Elsevier Inc.
dc.identifier.doi10.1016/j.urology.2017.09.005
dc.identifier.eissn1527-9995
dc.identifier.issn0090-4295
dc.identifier.pubmed28943369
dc.identifier.urihttps://hdl.handle.net/11424/234839
dc.identifier.wosWOS:000418721000042
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INC
dc.relation.ispartofUROLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectBOTULINUM-A TOXIN
dc.subjectINTRAVESICAL CAPSAICIN
dc.subjectBLADDER
dc.subjectHYPERREFLEXIA
dc.subjectNEUROTOXIN
dc.titleClinical and Urodynamic Results of Repeated Intradetrusor Onabotulinum Toxin A Injections in Refractory Neurogenic Detrusor Overactivity: Up to 5 Injections in a Cohort of Children With Myelodysplasia
dc.typearticle
dspace.entity.typePublication
local.avesis.id366de2a5-d703-4441-86e6-5b7c537d8876
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages8
local.journal.quartileQ3
oaire.citation.endPage175
oaire.citation.startPage168
oaire.citation.titleUROLOGY
oaire.citation.volume111
relation.isAuthorOfPublication1e489bdb-418e-4500-a522-6c0babb604b9
relation.isAuthorOfPublication.latestForDiscovery1e489bdb-418e-4500-a522-6c0babb604b9

Files

Collections

Research Outputs